NCT00924989已完成3 期
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 139
- 试验地点
- 35
- 主要终点
- Overall survival of single agent OSI-906 versus placebo
研究概览
简要总结
A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who received at least 1 but no more than 2 prior drug regimens
详细描述
Patients will be randomized 2:1 to receive either single agent OSI-906 (Arm A) or placebo (Arm B) and will be stratified according to prior systemic cytotoxic chemotherapy for ACC, and Eastern Cooperative Oncology Group (ECOG) performance status, and use of >= 1 oral antihyperglycemic therapy at randomization
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed adrenocortical carcinoma that is locally advanced or metastatic and not amenable to surgical resection.
- •Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1).
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) <= 2
- •Predicted life expectancy >= 12 weeks.
- •At least 1 but no more than 2 prior drug regimens (including molecular targeted therapy, systemic cytotoxic chemotherapy, biologics, and/or vaccines) for locally advanced/metastatic ACC.
- •A minimum of 3 weeks must have elapsed between the end of prior treatment and randomization.
- •All patients must have received prior mitotane, either as neoadjuvant, adjuvant, or locally advanced/metastatic therapy.
- •Adjuvant and neoadjuvant mitotane therapy will not be counted as prior drug regimens or as systemic cytotoxic chemotherapy.
- •Prior radiation therapy is permitted provided patients have recovered from the acute, toxic effects of radiotherapy prior to randomization.
- •A minimum of 21 days must have elapsed between the end of radiotherapy and randomization.
- •Prior surgery is permitted provided that adequate wound healing has occurred prior to randomization.
- •Fasting glucose < = 150 mg/dL (8.3 mmol/L).
- •Adequate hematopoietic, hepatic, and renal function defined as follows: Neutrophil count >= 1.5 x 10^9 /L;
- •Platelet count >= 100 x 10^9 /L;
- •Bilirubin <= 1.5 x Upper Limit of Normal (ULN);
- •AST and ALT <= 2.5 x ULN, or <= 5 x ULN if patient has documented liver metastases or received prior mitotane therapy; and
- •Serum creatinine <= 1.5 x ULN or <= 2.0 x ULN if the patient has received prior cisplatin.
- •Patients, both males and females, with reproductive potential (ie, menopausal for less than 1 year and not surgically sterilized) must agree to practice effective contraceptive measures throughout the study.
- •Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to randomization.
- •Patients must provide verbal and written informed consent to participate in the study.
- •Radiologically-confirmed progressive disease within 6 months prior to randomization.
- •Concurrent use of non-insulinotropic oral antihyperglycemic therapy is permitted if the dose has been stable for >= 4 weeks at the time of randomization.
排除标准
- •Type 1 diabetes mellitus or Type 2 diabetes mellitus currently requiring insulinotropic or insulin therapy.
- •Prior IGF-1R inhibitor therapy.
- •Malignancy other than ACC within the past 3 years. Exceptions: resected basal cell or squamous cell carcinoma of the skin; cured in situ cervical carcinoma; cured ductal carcinoma in situ of the breast; and/or cured superficial bladder cancer.
- •History of significant cardiovascular disease unless the disease is well-controlled.
- •Significant cardiac diseases includes second/third degree heart block; clinically significant ischemic heart disease; mean QTcF interval > 450 msec at screening;
- •poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea).
- •History of cerebrovascular accident (CVA) within 6 months prior to randomization or that resulted in ongoing neurologic instability.
- •Use of drugs that have a risk of causing QT interval prolongation within 14 days prior to Day 1 dosing.
- •Active infection or serious underlying medical condition (including any type of active seizure disorder within 12 months prior to randomization) that would impair the ability of the patient to receive study drug.
- •History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent.
- •Pregnant or breast-feeding females.
- •Symptomatic brain metastases that are not stable, require steroids, are potentially life threatening, or that have required radiation within 28 days prior to randomization.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drug.
研究组 & 干预措施
Arm A: OSI-906
Experimental
150 mg twice daily
干预措施: OSI-906 (Drug)
Arm B: Placebo
Placebo Comparator
Matching placebo twice daily
干预措施: Placebo (Other)
结局指标
主要结局
Overall survival of single agent OSI-906 versus placebo
时间窗: 33 months
Time from date of randomization until time of documented death
次要结局
- Time to deterioration in Quality of Life(24 months)
- Safety assessed via physical exams, vital signs, laboratory assessments, electrocardiograms, and adverse events(24 months)
- Progression-free survival(24 months)
- Disease control rate(24 months)
- Best overall response rate(24 months)
- Duration of response(24 months)
研究者
研究点 (35)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)Active Psoriatic ArthritisNCT04314544Sun Pharmaceutical Industries Limited508
已完成
3 期
Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic PurpuraThrombotic Thrombocytopenic PurpuraNCT05468320Sanofi51
已完成
3 期
Nasal Gel for the Prevention of Nausea and Vomiting Associated With MotionMotion SicknessNCT04947423Repurposed Therapeutics, Inc.140
已完成
3 期
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard TherapyRelapsed/Refractory Multiple MyelomaNCT02755597AbbVie291
终止
3 期
Parecoxib in Renal ColicColicNCT00139646Pfizer50